TWI368737B - Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway - Google Patents

Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Info

Publication number
TWI368737B
TWI368737B TW098143182A TW98143182A TWI368737B TW I368737 B TWI368737 B TW I368737B TW 098143182 A TW098143182 A TW 098143182A TW 98143182 A TW98143182 A TW 98143182A TW I368737 B TWI368737 B TW I368737B
Authority
TW
Taiwan
Prior art keywords
head
selection
treatment
cancer patients
neck cancer
Prior art date
Application number
TW098143182A
Other languages
English (en)
Chinese (zh)
Other versions
TW201028688A (en
Inventor
Heinrich Roder
Maxim Tsypin
Julia Grigorieva
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of TW201028688A publication Critical patent/TW201028688A/zh
Application granted granted Critical
Publication of TWI368737B publication Critical patent/TWI368737B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Artificial Intelligence (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
TW098143182A 2009-01-20 2009-12-16 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway TWI368737B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Publications (2)

Publication Number Publication Date
TW201028688A TW201028688A (en) 2010-08-01
TWI368737B true TWI368737B (en) 2012-07-21

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098143182A TWI368737B (en) 2009-01-20 2009-12-16 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Country Status (11)

Country Link
US (1) US7867775B2 (enExample)
EP (1) EP2247954B1 (enExample)
JP (1) JP5025802B2 (enExample)
KR (1) KR101131309B1 (enExample)
AT (1) ATE516503T1 (enExample)
AU (1) AU2009338174B2 (enExample)
CA (1) CA2718113A1 (enExample)
ES (1) ES2368784T3 (enExample)
IL (1) IL211943A (enExample)
TW (1) TWI368737B (enExample)
WO (1) WO2010085235A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
EP2539704A4 (en) * 2010-02-24 2015-12-02 Biodesix Inc CANCER PATIENT SELECTION FOR ADMINISTRATION OF THERAPEUTIC AGENTS USING MASS SPECTROMETRY ANALYSIS
EP2668504A4 (en) 2011-01-28 2015-06-10 Biodesix Inc PREDICTIVE TEST FOR SELECTING PATIENTS WITH METASTATIC BREAST CANCERS TO RECEIVE HORMONE THERAPY AND POLY THERAPY
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US8718996B2 (en) 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
CN112710723B (zh) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
EP3566054A4 (en) 2017-01-05 2020-12-09 Biodesix, Inc. PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY
WO2019032525A1 (en) 2017-08-07 2019-02-14 Genecentric Therapeutics, Inc. PROCESS FOR SUBTYPING EPIDERMOID CARCINOMA OF HEAD AND NECK
WO2019046585A1 (en) * 2017-08-30 2019-03-07 Genecentric Therapeutics, Inc. ANALYSIS OF GENE EXPRESSION SUB-TYPES OF EPIDERMOID CARCINOMA OF HEAD AND NECK FOR TREATMENT MANAGEMENT
EP3773691A4 (en) 2018-03-29 2022-06-15 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
CN116685259A (zh) * 2020-10-19 2023-09-01 本-古里安大学B.G.内盖夫技术和应用公司 尿细菌对抗生素的敏感性的快速直接鉴定和确定

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1540010B8 (en) 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
CA2527321A1 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
AU2005231101A1 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
EP2439285B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease

Also Published As

Publication number Publication date
ES2368784T3 (es) 2011-11-22
JP2011513728A (ja) 2011-04-28
IL211943A (en) 2014-01-30
US7867775B2 (en) 2011-01-11
AU2009338174B2 (en) 2012-02-02
KR101131309B1 (ko) 2012-04-02
EP2247954B1 (en) 2011-07-13
ATE516503T1 (de) 2011-07-15
JP5025802B2 (ja) 2012-09-12
IL211943A0 (en) 2011-06-30
WO2010085235A1 (en) 2010-07-29
TW201028688A (en) 2010-08-01
US20090171872A1 (en) 2009-07-02
EP2247954A1 (en) 2010-11-10
AU2009338174A1 (en) 2010-07-29
CA2718113A1 (en) 2010-07-29
HK1148073A1 (en) 2011-08-26
KR20110047171A (ko) 2011-05-06

Similar Documents

Publication Publication Date Title
TWI368737B (en) Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway
Nagel et al. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines
IL211944A (en) METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway
NZ710636A (en) Heterocyclic compounds and uses thereof
Hersh et al. Molecular pathways and genomic landscape of glioblastoma stem cells: opportunities for targeted therapy
Saki et al. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells
IN2014DN03447A (enExample)
Yu et al. Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells
Gurel et al. Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors
Lamtha et al. Cannabinoids as Promising Inhibitors of HER2-Tyrosine Kinase: A Novel Strategy for Targeting HER2-Positive Ovarian Cancer
Zhu et al. GRAIL inhibits the growth, migration and invasion of lung adenocarcinoma cells by modulating STAT3/C-MYC signaling pathways
Midde et al. Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment
Chaurasiya et al. Virtual screening for identification of novel potent EGFR inhibitors through AutoDock Vina molecular modeling software
Kim et al. ISU104, a fully human antibody targeting a specific epitope on the ErbB3, displays potent inhibition of tumor growth in multiple xenograft tumor models
莉芬趙 et al. Human Epidermal Growth Factor Receptor and Targeted Therapy for Breast Cancer
WO2013067136A3 (en) Assay for predictive biomarkers of anti-estrogen efficacy
Tutt Abstract PL04-02: Synthetic lethality: Targeting DNA repair mechanisms in clinical trials
Hariri Connexin-43 reduces tumor phenotype of mammary epithelial tumor cell line (MDA-MB231) through a context-dependent mechanism-by Hanaa Hassan Hariri
Sun et al. Treatment of inhibitors of tumor necrosis factor-a in endometriosis: Experimental study in vivo and in vitro
Lan et al. Abstract B29: Defining subclonal signaling heterogeneity in glioblastoma multiforme (GBM)
Ming et al. Detection of D2-40-positive lymphatic microvessel density and its clinical significance in lung cancer
Shen et al. NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance.
Moody et al. Generation of a fully human Gas6 neutralizing antibody with anti-tumor activity in vivo.
Zhang et al. Synthesis and Biological Activity of Multi-targeting Platinum (Ⅱ) Anticancer Complexes
Kirk Breast cancer cells—escape artists

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees